StockMarketWire.com - AstraZeneca said Friday that data showed its cancer treatment did not meet its primary object of improving overall survival compared with the standard of care.

The trial was examining the efficacy of Imfinzi monotherapy and the Imfinzi and tremelimumab combination in previously-untreated patients with Stage IV (metastatic) non-small cell, inoperable lung cancer.

The drugmaker said the data showed that its cancer treatment imfinzi monotherapy and the combination of Imfinzi plus tremelimumab had not improve overall survival -- one of the key metrics measured in the trial -- compared with the standard of care. 'We are encouraged to see that Imfinzi monotherapy activity is in-line with that of the anti-PD-1 class in previously-untreated patients with Stage IV non-small cell lung cancer; however, we are disappointed that these results missed statistical significance,' said Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer.

'We remain confident in Imfinzi as the cornerstone of our IO programme and continue to evaluate its potential in ongoing non-small cell lung cancer trials, including Imfinzi and Imfinzi plus tremelimumab in combination with chemotherapy.' Story provided by StockMarketWire.com